Cisen Pharmaceutical Co., Ltd. (SHA:603367)
China flag China · Delayed Price · Currency is CNY
14.31
-0.29 (-1.99%)
Sep 10, 2026, 1:44 PM CST

Cisen Pharmaceutical Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
3,3843,4273,9724,4514,0493,773
Other Revenue
14.1117.5610.0211.1416.839.62
3,3983,4453,9824,4624,0663,783
Revenue Growth
-6.92%-13.48%-10.77%9.74%7.50%2.95%
Cost of Revenue
1,6871,7341,8131,9131,8271,728
Gross Profit
1,7111,7112,1682,5502,2392,055
Selling, General & Admin
1,1131,1131,3671,6001,5441,455
Research & Development
291.65285.78342.64374.88335.17334.35
Other Operating Expenses
15.4330.4218.0220.9755.3750.31
Operating Expenses
1,4281,4401,7241,9991,9481,841
Operating Income
283.41270.96444.59550.79291.2214.24
Interest Expense
-0.87-1.34-6.95-6.59-4.29-6.1
Interest & Investment Income
211.89156.08101.8785.75390.18
Currency Exchange Gain (Loss)
-0.73-0.790.540.55-0.32-0.62
Other Non Operating Income (Expenses)
-6.96-0.33.65-1.27-0.175.21
EBT Excluding Unusual Items
486.74424.61543.71629.19339.41302.91
Gain (Loss) on Sale of Investments
49.6939.6810.53-10.37-3.12-6.09
Gain (Loss) on Sale of Assets
-1.05-0.71-0.140.590.970.27
Asset Writedown
-37.19-0.66-0.63-27.790.01-0.04
Other Unusual Items
26.8433.2722.34.2428.9239.09
Pretax Income
525.05496.19575.77595.86366.19336.13
Income Tax Expense
63.7670.5860.8370.4313.922.23
Earnings From Continuing Operations
461.28425.62514.94525.43352.27333.9
Minority Interest in Earnings
-4.76-4.37-6.03-4.09-2.310.24
Net Income
456.53421.25508.91521.34349.96334.15
Net Income to Common
456.53421.25508.91521.34349.96334.15
Net Income Growth
-2.40%-17.22%-2.38%48.97%4.73%-23.85%
Shares Outstanding (Basic)
456453454453454452
Shares Outstanding (Diluted)
456453454453454452
Shares Change
0.55%-0.31%0.23%-0.25%0.65%-0.18%
EPS (Basic)
1.000.931.121.150.770.74
EPS (Diluted)
1.000.931.121.150.770.74
EPS Growth
-2.93%-16.96%-2.61%49.35%4.05%-23.71%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
510.88401.61469.04433.53223.15182.58
Free Cash Flow Per Share
1.120.891.030.960.490.40
Dividend Per Share
0.1600.3480.4400.4360.3350.300
Dividend Growth
-60.78%-20.91%0.92%30.15%11.67%17.19%
Gross Margin
50.36%49.66%54.46%57.14%55.06%54.32%
Operating Margin
8.34%7.87%11.17%12.34%7.16%5.66%
Profit Margin
13.44%12.23%12.78%11.68%8.61%8.83%
Free Cash Flow Margin
15.03%11.66%11.78%9.71%5.49%4.83%
EBITDA
495.55466.28665.34781.54519.77432.08
EBITDA Margin
14.58%13.54%16.71%17.51%12.78%11.42%
D&A For EBITDA
212.13195.32220.74230.75228.57217.84
EBIT
283.41270.96444.59550.79291.2214.24
EBIT Margin
8.34%7.87%11.17%12.34%7.16%5.66%
Effective Tax Rate
12.14%14.22%10.56%11.82%3.80%0.66%
Revenue as Reported
3,3983,4453,9824,4624,0663,783
Advertising Expenses
-19.911.470.820.20.51